PETER WEINGOLD: Open Payments
NPI 1740202035 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,227 in 51 payments from 8 companies in 2025. Trend: 2023 $1,390 · 2024 $1,154 · 2025 $1,227
Food & beverage: $1,227
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $286 |
| Lundbeck LLC | 10 | $257 |
| ABBVIE INC. | 11 | $237 |
| Otsuka America Pharmaceutical, Inc. | 10 | $200 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $138 |
| Alkermes, Inc. | 2 | $57 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| E.R. Squibb & Sons, L.L.C. | 1 | $26 |
Products named: REXULTI, TRINTELLIX, VRAYLAR, CAPLYTA, LYBALVI, Auvelity, COBENFY.
Industry payments across CA — which companies pay providers there.
